↓ Skip to main content

Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men

Overview of attention for article published in The Journal of Clinical Endocrinology & Metabolism, October 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#2 of 12,792)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
265 news outlets
blogs
29 blogs
twitter
328 tweeters
patent
1 patent
facebook
20 Facebook pages
googleplus
1 Google+ user
video
12 video uploaders

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
248 Mendeley
Title
Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men
Published in
The Journal of Clinical Endocrinology & Metabolism, October 2016
DOI 10.1210/jc.2016-2141
Pubmed ID
Authors

Hermann M. Behre, Michael Zitzmann, Richard A. Anderson, David J. Handelsman, Silvia W. Lestari, Robert I. McLachlan, M. Cristina Meriggiola, Man Mohan Misro, Gabriela Noe, Frederick C. W. Wu, Mario Philip R. Festin, Ndema A. Habib, Kirsten M. Vogelsong, Marianne M. Callahan, Kim A. Linton, Doug S. Colvard

Abstract

The development of a safe and effective reversible method of male contraception is still an unmet need. Evaluation of suppression of spermatogenesis and contraceptive protection by coadministered im injections of progestogen and testosterone. Prospective multicentre study. Ten study centers. Healthy men, aged 18-45 years, and their 18- to 38-year-old female partners, both without known fertility problems. Intramuscular injections of 200-mg norethisterone enanthate combined with 1000-mg testosterone undecanoate, administered every 8 weeks. Suppression of spermatogenesis by ejaculate analysis, contraceptive protection by pregnancy rate. Of the 320 participants, 95.9 of 100 continuing users (95% confidence interval [CI], 92.8-97.9) suppressed to a sperm concentration less than or equal to 1 million/mL within 24 weeks (Kaplan-Meier method). During the efficacy phase of up to 56 weeks, 4 pregnancies occurred among the partners of the 266 male participants, with the rate of 1.57 per 100 continuing users (95% CI, 0.59-4.14). The cumulative reversibility of suppression of spermatogenesis after 52 weeks of recovery was 94.8 per 100 continuing users (95% CI, 91.5-97.1). The most common adverse events were acne, injection site pain, increased libido, and mood disorders. Following the recommendation of an external safety review committee the recruitment and hormone injections were terminated early. The study regimen led to near-complete and reversible suppression of spermatogenesis. The contraceptive efficacy was relatively good compared with other reversible methods available for men. The frequencies of mild to moderate mood disorders were relatively high.

Twitter Demographics

The data shown below were collected from the profiles of 328 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 248 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 1%
Unknown 245 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 69 28%
Student > Master 48 19%
Student > Ph. D. Student 29 12%
Researcher 26 10%
Other 13 5%
Other 34 14%
Unknown 29 12%
Readers by discipline Count As %
Medicine and Dentistry 75 30%
Biochemistry, Genetics and Molecular Biology 23 9%
Nursing and Health Professions 23 9%
Agricultural and Biological Sciences 23 9%
Psychology 13 5%
Other 54 22%
Unknown 37 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 2572. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 February 2021.
All research outputs
#1,278
of 17,144,747 outputs
Outputs from The Journal of Clinical Endocrinology & Metabolism
#2
of 12,792 outputs
Outputs of similar age
#22
of 300,683 outputs
Outputs of similar age from The Journal of Clinical Endocrinology & Metabolism
#2
of 166 outputs
Altmetric has tracked 17,144,747 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,792 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 300,683 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 166 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.